Exploring somatic mutations in BRAF, KRAS, and NRAS as therapeutic targets in Saudi colorectal cancer patients through massive parallel sequencing and variant classification
Overall, this study highlights the importance of comprehensive molecular screening and bioinformatics in understanding the mutational landscape of CRC in the Saudi population, ultimately improving targeted drug treatments.
Authors
- Ashraf A. El‐Harouni
- Hadiah Bassam Al Mahdi (ORCID: https://orcid.org/0000-0003-3483-9499)
- Zuhier Awan (ORCID: https://orcid.org/0000-0002-4176-335X)
- Babajan Banaganapalli (ORCID: https://orcid.org/0000-0001-8089-2210)
- Thamer Abdulhamid Aljuhani
- Ramu Elango (ORCID: https://orcid.org/0000-0003-4264-2135)
- Nuha Alrayes (ORCID: https://orcid.org/0000-0002-2389-6108)
- Rana Bokhary (ORCID: https://orcid.org/0000-0002-3372-1950)
- Rahaf Talal Alqawas
- Noor Ahmad Shaik (ORCID: https://orcid.org/0000-0002-8635-4947)
- Mahmood Al-Mutadares
Institutions
- King Abdulaziz University (SA)
- King Abdulaziz Hospital (SA)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-11-20
- DOI
- https://doi.org/10.3389/fphar.2024.1498295
- Citations
- 2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- King Abdulaziz University
- Khalifa University of Science, Technology and Research